Steadtrust LLC Acquires $1.3M Stake in Eli Lilly

The institutional investor added over 1,100 shares of the pharmaceutical giant in Q4 2025.

Apr. 11, 2026 at 9:37am

Got story updates? Submit your updates here. ›

A close-up view of complex pharmaceutical manufacturing equipment, including metal pipes, valves, and other industrial components, conveying the technical complexity and scale of the modern drug industry.An institutional investor's multi-million dollar stake in a major pharmaceutical company reflects the high-stakes, capital-intensive nature of modern drug development.Indianapolis Today

Steadtrust LLC, an institutional investor, acquired a new position in shares of Eli Lilly and Company (NYSE: LLY) during the fourth quarter of 2025. The firm purchased 1,197 shares of the pharmaceutical company's stock, valued at approximately $1.29 million.

Why it matters

Eli Lilly is one of the world's largest pharmaceutical companies, known for its innovative drug development and strong financial performance. This investment by Steadtrust LLC suggests the firm sees long-term growth potential in Lilly's business and pipeline.

The details

According to a recent 13F filing with the SEC, Steadtrust LLC added the Eli Lilly position in the fourth quarter of 2025. The 1,197 shares acquired represent a new stake for the institutional investor in the $888 billion pharmaceutical company.

  • Steadtrust LLC acquired the Eli Lilly shares in the fourth quarter of 2025.

The players

Steadtrust LLC

An institutional investment firm that acquired a new position in Eli Lilly and Company.

Eli Lilly and Company

A global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. Eli Lilly researches, develops, manufactures, and commercializes a broad range of medicines and therapies for patients worldwide.

Got photos? Submit your photos here. ›

The takeaway

This investment by Steadtrust LLC underscores the continued confidence in Eli Lilly's long-term growth prospects among institutional investors. As a leading pharmaceutical innovator, Lilly's strong pipeline and financial performance make it an attractive target for major funds seeking exposure to the healthcare sector.